Transactions
8
Insider / Arcutis Biotherapeutics, Inc.
Vairavan Latha
SVP Chief Financial Officer at Arcutis Biotherapeutics, Inc.
- Ticker
- ARQT
- First filing on record
- November 5, 2025
- Latest trade on record
- May 11, 2026
- SEC filings
- EDGAR ↗
Vairavan Latha, SVP Chief Financial Officer at Arcutis Biotherapeutics, Inc., has disclosed 8 transactions in ARQT since November 5, 2025: 0 purchases (0 open-market buys) and 6 sales, worth about $148K at the reported prices. The latest was filed May 13, 2026, 2 days after the trade.
Open-market buys
0
Sales
6
Avg. disclosure lag
2.3d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Vairavan Latha made no purchases and 6 sales worth $148K, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Vairavan Latha has traded 1 stock on record; the largest by dollars is ARQT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 6 | 6,037 | $148K |
| A | Grant or award | 2 | 97,000 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 7 | 0 | 5 · $146K |
| 2025 | 1 | 0 | 1 · $2,175 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ARQT | Sell S | May 11, 2026 | May 13, 2026 | 2d | 435 | $21 | $9,157 | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | May 4, 2026 | May 6, 2026 | 2d | 1,341 | $24 | $32K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Other A | February 27, 2026 | March 3, 2026 | 4d | 70,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| ARQT | Sell S | March 2, 2026 | March 3, 2026 | 1d | 81 | $26 | $2,099 | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | March 2, 2026 | March 3, 2026 | 1d | 2,772 | $25 | $70K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Other A | February 27, 2026 | March 3, 2026 | 4d | 27,000 | — | — | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | February 2, 2026 | February 4, 2026 | 2d | 1,320 | $25 | $34K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | November 3, 2025 | November 5, 2025 | 2d | 88 | $25 | $2,175 | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 13, 2026 | Form 4 | 0002065881-26-000004 | 1 | published | EDGAR ↗ |
| May 6, 2026 | Form 4 | 0002065881-26-000002 | 1 | published | EDGAR ↗ |
| March 3, 2026 | Form 4 | 0001628280-26-014325 | 4 | published | EDGAR ↗ |
| February 4, 2026 | Form 4 | 0001628280-26-005568 | 1 | published | EDGAR ↗ |
| November 5, 2025 | Form 4 | 0002065881-25-000035 | 1 | published | EDGAR ↗ |
Other insiders at Arcutis Biotherapeutics, Inc.
- Welgus Howard G. Director 49 rows
- Burnett Patrick See Remarks 29 rows
- Matsuda Masaru See Remarks 20 rows
- Watanabe Todd See Remarks 15 rows
- Leonard Keith R Director 13 rows
- Curran Terrie Director 11 rows
- Edwards Larry Todd See Remarks 8 rows
- Krishnamohan Neha Director 8 rows
- LIN SUE-JEAN Director 8 rows
- Gilbert Halley E Director 7 rows
Everyone on file, with contracts and lobbying under the company's name: Arcutis Biotherapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 8 | November 5, 2025 | May 13, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.